Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.

Also called NCT04433572

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Mercator MedSystems, Inc. (from the registry)
Registry
  • NCT NCT04433572
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04433572. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-30 (actual); primary completion 2028-02-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
Acronym
TANGO-3
Condition
Peripheral Artery Disease
Condition
Critical Limb Ischemia
Intervention (Drug)
Temsirolimus
Intervention (Drug)
Saline placebo
Lead sponsor
Mercator MedSystems, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04433572
Content hash
67b9c50814b0374c41501f0b9b6f02015bd571c43cb597711b74f29e781ce272